Drug Etiology of Aplastic Anemia and Related Dyscrasias
NCT00005302 · Status: COMPLETED · Type: OBSERVATIONAL
Last updated 2016-05-13
Summary
To determine the role of drugs in the etiology of aplastic anemia, agranulocytosis, and thrombocytopenic purpura. Drugs used in chemotherapy and immunotherapy were excluded.
Conditions
- Blood Disease
- Anemia, Aplastic
- Agranulocytosis
- Purpura, Thrombocytopenic
Sponsors & Collaborators
-
National Heart, Lung, and Blood Institute (NHLBI)
lead NIH
Eligibility
- Max Age
- 100 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1985-04-30
- Completion
- 1992-06-30
More Related Trials
-
A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients
NCT00922883 ·Status: COMPLETED ·Phase: PHASE2
-
An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA
NCT05333861 ·Status: NOT_YET_RECRUITING
-
A Trial of Hetrombopag in Healthy and Hepatic Impairment Subjects
NCT05088642 ·Status: COMPLETED ·Phase: PHASE1
-
Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia
NCT01623167 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Effectiveness of Early Intervention in Transfusion Independent Aplastic Anemia: a Retrospective Medical Claims Database Study
NCT06669221 ·Status: COMPLETED
-
A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone
NCT02050581 ·Status: TERMINATED
-
Immune Thrombocytopenia Management in Adults
NCT05861297 ·Status: UNKNOWN ·Phase: PHASE4
-
Real-world Outcomes of Aplastic Anemia Patients Treated With Eltrombopag: A Medical Claims Database Study
NCT06991894 ·Status: COMPLETED
-
Eltrombopag for Moderate Aplastic Anemia
NCT01328587 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia
NCT02094417 ·Status: COMPLETED ·Phase: PHASE2
-
AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy
NCT00102323 ·Status: COMPLETED ·Phase: PHASE3
-
Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic Purpura
NCT06137105 ·Status: NOT_YET_RECRUITING
-
Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura
NCT00005652 ·Status: COMPLETED ·Phase: PHASE2
-
The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias
NCT00472433 ·Status: TERMINATED ·Phase: PHASE2
-
Role of Acute Phase Proteins In Diagnosis of Immune Thrombocytopenia
NCT06715215 ·Status: RECRUITING ·Phase: NA
-
Platelet Reactivity In Patients With Nuisance Bleeding On A Thienopyridine
NCT01152229 ·Status: COMPLETED
-
Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia
NCT02773290 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
The Outcome of the Thrombopoietin Receptor Agonists in Pediatric Patient With Persistent or Chronic ITP Unresonsive to Steroids
NCT06568913 ·Status: RECRUITING ·Phase: NA
-
Herombopag + rhTPO in Severe Immune Thrombocytopenia
NCT05328804 ·Status: UNKNOWN ·Phase: PHASE3
-
Bleeding In Thrombocytopenia Explained
NCT03505086 ·Status: RECRUITING
-
Daclizumab to Treat Chronic Immune Thrombocytopenia
NCT00049725 ·Status: COMPLETED ·Phase: PHASE2
-
The Association Between Platelet Reactivity and Bleeding Risk in Adult ITP
NCT03377439 ·Status: UNKNOWN
-
National Multicenter Retrospective Real-World Study on the Treatment Status of Newly Diagnosed and Persistent Primary Immune Thrombocytopenia (ITP) Patients
NCT07268898 ·Status: NOT_YET_RECRUITING
-
A Trial of Hetrombopag in Healthy Subjects
NCT05088174 ·Status: COMPLETED ·Phase: PHASE1
-
Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP)
NCT01443351 ·Status: WITHDRAWN